HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Naphazoline Hydrochloride

HCID 11079
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
550-99-2
Standard SMILES
Cl.c1ccc2c(CC3=NCCN3)cccc2c1
InChIKey
DJDFFEBSKJCGHC-UHFFFAOYSA-N
Molecular formula
C14H14N2.ClH
Average molar mass
246.73 g/mol
Monoisotopic mass
246.0923762

Overview

Naphazoline is an organic molecular entity.

Names & identifiers

Preferred name
Naphazoline Hydrochloride
IUPAC
2-(naphthalen-1-ylmethyl)-4,5-dihydro-1H-imidazole;hydrochloride
English name
Naphazoline hydrochloride
Molecular formula
C14H14N2.ClH
Molecular weight
246.74

Names & synonyms

NAPHAZOLINE HYDROCHLORIDE550-99-2NAPHAZOLINE HCLAlbalonVasoconOpconRhinantinRhinoperdStricylonNiazolNaphcon fortePrivine hydrochloride
Show more names
Naphazoline hydrochloride (Naphcon)4,5-DIHYDRO-2-(1-NAPHTHYLMETHYL)-1H-IMIDAZOLE HYDROCHLORIDEcleranaphcon
2-(1-Naphthylmethyl)-2-imidazoline hydrochlorideNaphazoline chlorideColdanSanorinPrizole hydrochlorideNAFAZAIRDTXSID7045788NSC-35711

Database identifiers

CAS
550-99-2
PubChem CID
11079
DTXSID
DTXSID7045788
ChEMBL
CHEMBL1706
ChEBI
CHEBI:7470
UNII
MZ1131787D
EC Number
208-989-2

Properties

Computed structural properties

Topological polar surface area
24.4 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
1
Rotatable bonds
2
Heavy atoms
17
Formal charge
0
Complexity
272

Experimental & physicochemical properties

pHA 1% aqueous solution has a pH of about 6.2
OdorODORLESS
TasteBitter
Color/FormWHITE CRYSTALLINE POWDER
Solubility · 3 items

Soluble in ethanol; slightly soluble in chlorform; insoluble in benzene and ether

In water, 4.0X10+5 mg/L at 25 °C

>37 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point255-260 °C
Stability/Shelf LifeNAPHAZOLINE HYDROCHLORIDE WAS STABLE FOR 2 MO @ 5 & 15 °C.
Dissociation ConstantspKa = 10.35 (25 °C); pKa = 10.13 (35 °C); pKa = 9.92 (45 °C)
Collision Cross Section148.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H300 (86.3%): Fatal if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 51 reports by companies from 7 notifications to the ECHA C&L Inventory.

Hazard information

Regulatory Information · 2 items

Chemical: 1H-Imidazole, 4,5-dihydro-2-(1-naphthalenylmethyl)-, monohydrochloride

NAPHAZOLINE HYDROCHLORIDE: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 1H-Imidazole, 4,5-dihydro-2-(1-naphthalenylmethyl)-, monohydrochloride: Environment tier I assessment
FDA Requirements · 3 items

Nasal decongestant active ingredients. The active ingredient of the product consists of any of the following when used within the dosage limits and in the dosage forms established for each ingredient: ... Topical nasal decongestants: naphazoline hydrochloride.

Ophthalmic vasoconstrictors. The active ingredient of the product consists of one of the following, within the established concentration for each ingredient: ... Naphazoline hydrochloride, 0.01 to 0.03 percent.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription and over-the-counter drug products, incl naphazoline hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

DOT Emergency Guidelines · 5 items

/GUIDE 154: SUBSTANCES - TOXIC AND/OR CORROSIVE (NON-COMBUSTIBLE)/ Health: TOXIC; inhalation, ingestion, or skin contact with material may cause severe injury or death. Contact with molten substance may cause severe burns to skin and eyes. Avoid any skin contact. Effects of contact or inhalation may be delayed. Fire may produce irritating, corrosive and/or toxic gases. Runoff from fire control or dilution water may be corrosive and/or toxic and cause pollution. /Poisonous solid, organic, NOS; Toxic solid, organic, NOS (Naphazoline hydrochloride)/

Chemistry & industry

Pharmacology

Mechanism of Action · 2 items

Naphazoline constricts the vascular system of the conjunctiva. It is presumed that this effect is due to direct stimulation action of the drug upon the alpha-adrenergic receptors in the arterioles of the conjunctiva, resulting in decreased conjunctival congestion.

The mechanism of action of naphazoline has not been conclusively determined. Most pharmacologists believe that the drug directly stimulates alpha-adrenergic receptors of the sympathetic nervous system and exerts little or no effect on beta-adrenergic receptors. Following topical application of naphazoline to the conjunctiva, small arterioles are constricted and conjunctival congestion is temporarily relieved, but reactive hyperemia may occur. The drug also may produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants.

MeSH Pharmacological Classification · 2 items

Drugs that selectively bind to and activate alpha adrenergic receptors.

Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993)

Absorption, Distribution and Excretion · 1 item

Following topical application of naphazoline hydrochloride solutions to the conjunctiva, local vasoconstriction usually occurs within 10 minutes and may persist for 2-6 hours. Occasionally, enough naphazoline may be absorbed to produce systemic effects. Information on the distribution and elimination of the drug in humans is not available

Uses & manufacturing

Uses · 3 items

THERAP CAT: Adrenergic (vasoconstrictor); decongestant /Naphazoline/

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Other Experimental PropertiesDECOMP @ 253-258 °C

Physicochemical properties

Melting point
254 · 254-260 °C
storage temp.
Keep in dark place,Inert atmosphere,Room temperature
solubility
Freely soluble in water, soluble in ethanol (96 per cent).
pka
pKa (25°C) 10.35 ±0.02, (35°C) 10.13 ±0.02, (45°C) 9.92 ±0.03; pKa (25°C) 10.35 ±0.02, (35°C) 10.13 ±0.02, (45°C) 9.92 ±0.03
form
Crystalline Powder
color
White
PH
pH (50g/l, 25℃) : 4.0~6.0
Water Solubility
170 g/L · 170 g/L (20 ºC)
Sensitive
Hygroscopic
Merck
14 · 14,6368
BRN
3716843 · 3716843
Stability
Hygroscopic
Major Application
pharmaceutical (small molecule)
Cosmetics Ingredients Functions
SKIN CONDITIONING - MISCELLANEOUS
InChI
InChI=1S/C14H14N2.ClH/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14;/h1-7H,8-10H2,(H,15,16);1H
InChIKey
DJDFFEBSKJCGHC-UHFFFAOYSA-N
SMILES
C(C1C2C(=CC=CC=2)C=CC=1)C1NCCN=1.[H]Cl
CAS DataBase Reference
550 · 550-99-2(CAS DataBase Reference)
FDA 21 CFR
341.2 · 341.20
EWG's Food Scores
1 · 1
FDA UNII
1131787 D · MZ1131787D
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
300 · H300
Precautionary statements
264 · P264-P270-P301+P310+P330-P405-P501-P301+P310a-P321-P501a
Hazard Codes
T,Xn
Risk Statements
25 · 25-23/24/25-20/21/22
Safety Statements
45 · 45-36/37/39-24/25
RIDADR
2811 · UN 2811 6.1/PG 2
WGK Germany
3 · 3
RTECS
4375000 · NJ4375000
HazardClass
6.1 · 6.1
PackingGroup
III
HS Code
29339900 · 29339900
Storage Class
11 · 11 - Combustible Solids
Hazardous Substances Data
550 · 550-99-2(Hazardous Substances Data)
Toxicity
50 s.c · LD50 s.c. in rats: 385 mg/kg (Gylfe)

/GUIDE 154: SUBSTANCES - TOXIC AND/OR CORROSIVE (NON-COMBUSTIBLE)/ Fire or Explosion: Non-combustible, substance itself does not burn but may decompose upon heating to produce corrosive and/or toxic fumes. Some are oxidizers and may ignite combustibles (wood, paper, oil, clothing, etc.). Contact with metals may evolve flammable hydrogen gas. Containers may explode when heated. /Poisonous solid, organic, NOS; Toxic solid, organic, NOS (Naphazoline hydrochloride)/

/GUIDE 154: SUBSTANCES - TOXIC AND/OR CORROSIVE (NON-COMBUSTIBLE)/ Public Safety: CALL Emergency Response Telephone Number ... . As an immediate precautionary measure, isolate spill or leak area in all directions for at least 50 meters (150 feet) for liquids and at least 25 meters (75 feet) for solids. Keep unauthorized personnel away. Stay upwind. Keep out of low areas. Ventilate enclosed areas. /Poisonous solid, organic, NOS; Toxic solid, organic, NOS (Naphazoline hydrochloride)/

/GUIDE 154: SUBSTANCES - TOXIC AND/OR CORROSIVE (NON-COMBUSTIBLE)/ Protective Clothing: Wear positive pressure self-contained breathing apparatus (SCBA). Wear chemical protective clothing that is specifically recommended by the manufacturer. It may provide little or no thermal protection. Structural firefighters' protective clothing provides limited protection in fire situations ONLY; it is not effective in spill situations where direct contact with the substance is possible. /Poisonous solid, organic, NOS; Toxic solid, organic, NOS (Naphazoline hydrochloride)/

For more DOT Emergency Guidelines (Complete) data for NAPHAZOLINE HYDROCHLORIDE (8 total), please visit the HSDB record page.

Hazard Classes and CategoriesAcute Tox. 2 (86.3%)

Safety & protection

Storage Conditions · 1 item

Naphazoline hydrochloride ophthalmic solutions should be protected from light and should be stored in tight, light-resistant containers. The drug is degraded in the presence of aluminum and, therefore, should not be stored in aluminum containers. ... Fixed combinations containing naphazoline hydrochloride and antazoline phosphate should be stored at temperatures less than 25 °C.

Disposal Methods · 1 item

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxicology

Interactions · 3 items

Patients being treated with monoamine oxidase (MAO) inhibitors may experience a severe hypertensive reaction if administered with a sympathomimetic drug. Although this reaction has not specifically been reported with naphazoline, the possibility of such an interaction should be considered.

Concurrent use of maprotiline or tricyclic antidepressants with naphazoline hydrochloride may potentiate the pressor effects of naphazoline.

PENTOBARBITONE APPEARS TO ENHANCE HYPOTENSIVE ACTION OF ALPHA-SYMPATHOMIMETIC DRUGS, INCL NAPHAZOLINE HYDROCHLORIDE.

Human Toxicity Excerpts · 5 items

/SIGNS AND SYMPTOMS/ Overdosage of the drug may produce drowsiness, decreased body temperature, bradycardia, shock-like hypotension, and coma.

/SIGNS AND SYMPTOMS/ Excessive dosage of topically applied naphazoline hydrochloride may cause marked sedation in children, and, if severe, symptomatic and supportive therapy should be initiated. One manufacturer states that 0.1% naphazoline hydrochloride ophthalmic solution is contraindicated in infants and children, since CNS depression possibly progressing to coma and hypothermia may occur in children, especially infants.

/SIGNS AND SYMPTOMS/ Naphazoline, a sympathomimetic and an imidazoline derivative, is used as 0.05-0.1% solution for local decongestion of the nasal and ocular mucosa. In excessive dosage, or if ingested by accident, may cause depression of the central nervous system (disturbances of consciousness progressing to coma), hypothermia, bradycardia and sweating. These naphazoline effects are particularly strongly pronounced in children. Anglo-Saxon pharmacotherapy excludes the application of naphazoline nasal drops in children younger than six years, whereas the Croatian pharmacotherapeutic literature (and practice) allows its use even in infancy. At the Kantrida Pediatric Clinic, Clinical Hospital Center in Rijeka, 11 children with signs of intoxication with naphazoline nasal drops were hospitalized from 1990 to 1992. The symptoms pertaining to the central nervous system i.e. disturbances of consciousness in the form of somnolence were clearly marked in all children. Some children developed skin pallor, bradycardia, bradypnoea and hypothermia. Resolution occurred within 24 hours and the findings returned to normal values. Clinical picture followed by rapid resolution and normal findings, with a personal history of drug taking, is a safe indication for diagnosis. There are several reasons to account for intoxication (drops difficult to use with children, containers inadequate for proper dosage), but the major factor is the age of the patient--all hospitalized children were younger than six years.

/SIGNS AND SYMPTOMS/ It is reported that many accidental poisonings in Japan are the result of ingestion of dermatologic preparations containing naphazoline hydrochloride; symptoms include somnolence, elevation of blood pressure, and bradycardia.

For more Human Toxicity Excerpts (Complete) data for NAPHAZOLINE HYDROCHLORIDE (11 total), please visit the HSDB record page.

Non-Human Toxicity Excerpts · 1 item

/OTHER TOXICITY INFORMATION/ In dogs, signs of intoxication may include vomiting, bradycardia, cardiac arrhythmias, poor capillary refill time, hypotension or hypertension, panting, increased upper respiratory sounds, depression, weakness, nervousness, hyperactivity, or shaking. These signs appear within 30 min to 4 hr postexposure. In general, imidazoline decongestant exposure may affect the GI, cardiopulmonary, and nervous systems. /Imidazoline decongestions/

Populations at Special Risk · 3 items

Patients with glaucoma should be advised not to use naphazoline hydrochloride ophthalmic solutions except under the advice and supervision of a physician. Ophthalmic solutions of the drug should not be used in patients with angle-closure glaucoma.

One manufacturer states that 0.1% naphazoline hydrochloride ophthalmic solution is contraindicated in infants and children, since CNS depression possibly progressing to coma and hypothermia may occur in children, especially infants.

Naphazoline hydrochloride ophthalmic solution should be used with caution in patients with hypertension, cardiovascular abnormalities, diabetes mellitus, hyperthyroidism, ... .

Antidote and Emergency Treatment · 2 items

/VET:/ Decontamination may not be practical due to the rapid absorption and onset of clinical signs. Heart rate and rhythm and blood pressure should be assessed, and an ECG obtained if needed. IV fluids should be given, along with atropine at 0.02 mg/kg, IV, if bradycardia is present. Diazepam (0.25-0.5 mg/kg, IV) can be given if CNS signs (eg, apprehension, shaking) are present. Serum electrolytes (ie, potassium, sodium, chloride) should be assessed and corrected as needed. Yohimbine, which is a specific a2-adrenergic antagonist, can also be used at 0.1 mg/kg, IV, and repeated in 2-3 hr if needed. /Imidazoline decongestants/

No specific antidote is available but a symptomatic drug therapy with intravenous administration of phentolamine, an alpha-adrenoceptor antagonist acts against the vasoconstrictive side effects. Because of the serious side effects and the narrow therapeutic to toxic window of naphazoline a strict observance of guidelines and contradictions, such as maximum dose, is necessary.

Non-Human Toxicity ValuesLD50 Rat sc 385 mg/kg

Regulatory information

FDA Requirements · 3 items

Nasal decongestant active ingredients. The active ingredient of the product consists of any of the following when used within the dosage limits and in the dosage forms established for each ingredient: ... Topical nasal decongestants: naphazoline hydrochloride.

Ophthalmic vasoconstrictors. The active ingredient of the product consists of one of the following, within the established concentration for each ingredient: ... Naphazoline hydrochloride, 0.01 to 0.03 percent.

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription and over-the-counter drug products, incl naphazoline hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Safety data

wgk
3
rtecs
NJ4375000
ridadr
UN 2811 6.1/PG 2
hs_code
29339900
Toxicity
LD50 s.c. in rats: 385 mg/kg (Gylfe)
risk_code
25-23/24/25-20/21/22
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T,Xn
safety_code
45-36/37/39-24/25
hazard_class
6.1
Storage Class
11 - Combustible Solids
packing_group
III
Hazard statements
H300
Precautionary statements
P264-P270-P301+P310+P330-P405-P501-P301+P310a-P321-P501a
Hazardous Substances Data
550-99-2(Hazardous Substances Data)

MEDICATION

The imidazoline derivative naphazoline, an alpha-2-adrenergic agonist, is used as non-prescription eye and nasal preparation because of its vasoconstrictive and decongestive properties.

Methods of ManufacturingIN ALMOST QUANTITATIVE YIELDS BY HEATING 1-NAPHTHYLACETONITRILE WITH ETHYLENEDIAMINE MONOHYDROCHLORIDE @ 175 TO 200 °C FOR 1 HR. AMMONIA IS...BY-PRODUCT.
Formulations/Preparations · 3 items

Ophthalmic: Solution: 0.012% All Clear ( with benzalkonium chloride), (Bausch & Lomb), Clear Eyes ( with benzalkonium chloride and glycerin 0.2%), (Prestige Brands), Naphcon ( with benzalkonium chloride), (Alcon); 0.03% All Clear AR ( with benzalkonium chloride), (Bausch & Lomb); 0.1% AK-Con ( with benzalkonium chloride), (Akorn), Albalon ( with benzalkonium chloride), (Allergan), Naphazoline Hydrochloride Ophthalmic Solution, (Bausch & Lomb).

Ophthalmic: Solution: 0.012% with Zinc Sulfate 0.25% Clear Eyes ACR ( with benzalkonium chloride and glycerin 0.2%), (Prestige Brands); 0.025% with Pheniramine Maleate 0.3% Naphcon-A (with benzalkonium chloride), (Alcon) Visine A , (Pfizer); 0.027% with Pheniramine Maleate 0.315% Opcon A, (Bausch & Lomb); 0.05% with Antazoline Phosphate 0.5% Vasocon-A ( with benzalkonium chloride), (Novartis).

Trade names: Ak-Con (Akorn); Albalon (Allergan); Allerest Eye Drops (Pharmacraft); Allergy Drops (Bausch & Lomb); Clear Eyes (Ross); Clera (Person and Covey); Comfort Eye Drops, Degest 2 (Barnes-Hind); Imidazyl (Allergan); Naphcon (Alcon); I-Naphline (Americal); Opcon (Bausch & Lomb); Optazine (Lederle); Otrivin, Privin, Privina, Privine (Ciba); Vasocon Regular (IOLAB).

Applications · 4 items

UsesThis product is a vasoconstrictor. Rat subcutaneous injection is LD50 385 mg/kg.

UsesNaphazoline Hydrochloride is a useful synthetic intermediate used in eye drops. A vasoconstrictor.

Usesadrenergic blocker

Usesantihistamine

Upstream & downstream products

Upstream raw materials

1-Methylimidazole1-Naphthaleneacetic acidImidazolidineEthylenediamine

Additional notes

DefinitionChEBI: Naphazoline is an organic molecular entity.